



Clinical trial results:

A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of four 12-week treatment cycles (48 weeks total) of epratuzumab in systemic lupus erythematosus subjects with moderate to severe disease

Summary

EudraCT number	2010-018565-26
Trial protocol	HU ES DE GB IT
Global end of trial date	03 June 2015

Results information

Result version number	v2 (current)
This version publication date	06 December 2020
First version publication date	18 June 2016
Version creation reason	<ul style="list-style-type: none">• Correction of full data set Alignment with final posting on ClinicalTrials.gov after NIH review.

Trial information

Trial identification

Sponsor protocol code	SL0010
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01261793
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	UCB, Inc.
Sponsor organisation address	1950 Lake Park Drive, Smyrna, United States, GA 30080
Public contact	Clin Trial Reg and Results Disclosure, UCB BIOSCIENCES GmbH, +49 2173 48 15 15, clinicaltrials@ucb.com
Scientific contact	Clin Trial Reg and Results Disclosure, UCB BIOSCIENCES GmbH, +49 2173 48 15 15, clinicaltrials@ucb.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	09 July 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	18 May 2015
Global end of trial reached?	Yes
Global end of trial date	03 June 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study is to confirm the clinical efficacy of epratuzumab in the treatment of subjects with moderately to severely active Systemic Lupus Erythematosus (SLE) despite standard of care treatments (ie, corticosteroids and potentially antimalarials and immunosuppressants) continued from Baseline.

Protection of trial subjects:

Patients were pre-medicated prior to infusion of Investigational Medicinal Product (IMP) to prevent infusion reactions. During the conduct of the study all subjects were closely monitored.

Background therapy:

- Subjects must be receiving concomitant oral corticosteroids within the range of 5 to 60 mg/day prednisone equivalents, dependent on the investigator's assessment of disease activity, at a stable dose for at least 5 days (± 1 day) prior to Week 0 (Visit 2) and the first study drug infusion. Tapering of oral corticosteroids after Week 4 (Visit 6) to a target dose of ≤ 7.5 mg/day prednisone equivalents is encouraged during the study.
- If the subject is receiving concomitant antimalarials, they must have been receiving them for at least 12 weeks prior to Screening/Baseline (Visit 1), with a stable dose regimen for at least 28 days (± 1 day) prior to Week 0 (Visit 2) and the first study drug infusion. The antimalarial dose should be continued at a stable dose (same as Baseline dose) during the study.
- If the subject is receiving concomitant immunosuppressants, they must be on a stable dose for at least 28 days (± 1 day) prior to Week 0 (Visit 2) and the first study drug infusion. The immunosuppressants dose should be continued at a stable dose (same as Baseline dose) during the study.
- Subjects receiving memantine, bromocriptine (Parlodel), danazol, dapsone, dehydroepiandrosterone, or retinoids must be on a stable dose for 28 days (± 1 day) prior to Visit 2 and the first study drug infusion. The dose must remain stable during the study until Week 24 (Visit 14), after which time it may be held stable or decreased based on the investigator's judgment of the subject's disease activity and health status.

Evidence for comparator:

Not applicable

Actual start date of recruitment	22 December 2010
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	4 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Brazil: 51
Country: Number of subjects enrolled	Canada: 27
Country: Number of subjects enrolled	France: 11

Country: Number of subjects enrolled	Germany: 41
Country: Number of subjects enrolled	Hungary: 44
Country: Number of subjects enrolled	India: 4
Country: Number of subjects enrolled	Italy: 9
Country: Number of subjects enrolled	Mexico: 31
Country: Number of subjects enrolled	Poland: 154
Country: Number of subjects enrolled	Romania: 20
Country: Number of subjects enrolled	Russian Federation: 12
Country: Number of subjects enrolled	South Africa: 20
Country: Number of subjects enrolled	Spain: 24
Country: Number of subjects enrolled	Ukraine: 53
Country: Number of subjects enrolled	United Kingdom: 6
Country: Number of subjects enrolled	United States: 284
Worldwide total number of subjects	791
EEA total number of subjects	309

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	767
From 65 to 84 years	24
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study started to enroll patients in December 2010 and concluded in June 2015.

Pre-assignment

Screening details:

Participant Flow refers to the Randomized Set (RS).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Assessor, Subject, Investigator, Carer

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo (Weekly infusion) (RS)

Arm description:

Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	PBO
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

weekly

Arm title	Epratuzumab 1200 mg every other week (RS)
------------------	---

Arm description:

1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	PBO
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

weekly

Investigational medicinal product name	Epratuzumab
Investigational medicinal product code	Emab
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

600 mg every week or 1200 mg every other week

Arm title	Epratuzumab 600 mg weekly (RS)
------------------	--------------------------------

Arm description:

600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles

Arm type	Experimental
Investigational medicinal product name	Epratuzumab
Investigational medicinal product code	Emab
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

600 mg every week or 1200 mg every other week

Number of subjects in period 1	Placebo (Weekly infusion) (RS)	Epratuzumab 1200 mg every other week (RS)	Epratuzumab 600 mg weekly (RS)
Started	263	262	266
Completed	178	171	184
Not completed	85	91	82
Adverse event, serious fatal	3	1	-
Randomization error	-	1	-
Patient non-compliance	1	-	1
Outside the study area	-	2	1
Patient withdrew after cardiology visit	-	1	-
Patient pregnant	1	-	-
Consent withdrawn by subject	12	14	14
Suspected pregnancy	1	1	-
Patient unable to start IV line	-	-	1
Lack of efficacy & patient not available	-	1	-
Adverse event, non-fatal	9	24	19
Patient non-availability	1	1	1
Lost to follow-up	10	3	7
Lack of efficacy	44	37	32
Protocol deviation	3	5	6

Baseline characteristics

Subject analysis sets

Subject analysis set title	Placebo (Weekly infusion) (SS)
Subject analysis set type	Safety analysis
Subject analysis set description: Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles	
Subject analysis set title	Epratuzumab 1200 mg every other week (SS)
Subject analysis set type	Safety analysis
Subject analysis set description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles	
Subject analysis set title	Epratuzumab 600 mg weekly (SS)
Subject analysis set type	Safety analysis
Subject analysis set description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles	
Subject analysis set title	Placebo (Weekly infusion) (FAS)
Subject analysis set type	Full analysis
Subject analysis set description: Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles	
Subject analysis set title	Epratuzumab 1200 mg every other week (FAS)
Subject analysis set type	Full analysis
Subject analysis set description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles	
Subject analysis set title	Epratuzumab 600 mg weekly (FAS)
Subject analysis set type	Full analysis
Subject analysis set description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles	

Reporting group values	Placebo (Weekly infusion) (SS)	Epratuzumab 1200 mg every other week (SS)	Epratuzumab 600 mg weekly (SS)
Number of subjects	263	261	264
Age categorical Units: Subjects			
≤18 years	0	0	0
Between 18 and 65 years	254	257	254
≥65 years	9	4	10
Age continuous Units: years			
arithmetic mean	41.1	40.8	41.2
standard deviation	± 11.8	± 11.5	± 12.7
Gender categorical Units: Subjects			
Male	18	14	19
Female	245	247	245

Reporting group values	Placebo (Weekly infusion) (FAS)	Epratuzumab 1200 mg every other week (FAS)	Epratuzumab 600 mg weekly (FAS)
Number of subjects	263	261	264
Age categorical Units: Subjects			
<=18 years	0	0	0
Between 18 and 65 years	254	257	254
>=65 years	9	4	10
Age continuous Units: years			
arithmetic mean	41.1	40.8	41.2
standard deviation	± 11.8	± 11.5	± 12.7
Gender categorical Units: Subjects			
Male	18	14	19
Female	245	247	245

End points

End points reporting groups

Reporting group title	Placebo (Weekly infusion) (RS)
Reporting group description: Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles	
Reporting group title	Epratuzumab 1200 mg every other week (RS)
Reporting group description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles	
Reporting group title	Epratuzumab 600 mg weekly (RS)
Reporting group description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles	
Subject analysis set title	Placebo (Weekly infusion) (SS)
Subject analysis set type	Safety analysis
Subject analysis set description: Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles	
Subject analysis set title	Epratuzumab 1200 mg every other week (SS)
Subject analysis set type	Safety analysis
Subject analysis set description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles	
Subject analysis set title	Epratuzumab 600 mg weekly (SS)
Subject analysis set type	Safety analysis
Subject analysis set description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles	
Subject analysis set title	Placebo (Weekly infusion) (FAS)
Subject analysis set type	Full analysis
Subject analysis set description: Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles	
Subject analysis set title	Epratuzumab 1200 mg every other week (FAS)
Subject analysis set type	Full analysis
Subject analysis set description: 1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles	
Subject analysis set title	Epratuzumab 600 mg weekly (FAS)
Subject analysis set type	Full analysis
Subject analysis set description: 600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles	

Primary: The percent of subjects meeting treatment response criteria at Week 48 according to a combined response index

End point title	The percent of subjects meeting treatment response criteria at Week 48 according to a combined response index
End point description: Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study	

entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.

The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.

End point type	Primary
End point timeframe:	
At Week 48	

End point values	Placebo (Weekly infusion) (FAS)	Epratuzumab 1200 mg every other week (FAS)	Epratuzumab 600 mg weekly (FAS)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	263	261	264	
Units: Percentage of responders				
number (not applicable)				
Responder	33.5	34.1	35.2	

Statistical analyses

Statistical analysis title	Statistical Analysis 1
-----------------------------------	------------------------

Statistical analysis description:

Odds ratio: Epratuzumab/Placebo calculated using logistic regression with factors for treatment, pooled region, and baseline disease status.

Comparison groups	Placebo (Weekly infusion) (FAS) v Epratuzumab 1200 mg every other week (FAS)
Number of subjects included in analysis	524
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.899 ^[1]
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.024
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.71
upper limit	1.477

Notes:

[1] - p-values for the comparison of treatment groups have been calculated using logistic regression with factors for treatment, pooled region, and baseline disease status.

Statistical analysis title	Statistical Analysis 2
-----------------------------------	------------------------

Statistical analysis description:

Odds ratio: Epratuzumab/Placebo calculated using logistic regression with factors for treatment, pooled region, and baseline disease status.

Comparison groups	Placebo (Weekly infusion) (FAS) v Epratuzumab 600 mg weekly (FAS)
-------------------	---

Number of subjects included in analysis	527
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.716 ^[2]
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.743
upper limit	1.539

Notes:

[2] - p-values for the comparison of treatment groups have been calculated using logistic regression with factors for treatment, pooled region, and baseline disease status.

Secondary: The percent of subjects meeting treatment response criteria at Week 24 according to a combined response index

End point title	The percent of subjects meeting treatment response criteria at Week 24 according to a combined response index
-----------------	---

End point description:

Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.

The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 24

End point values	Placebo (Weekly infusion) (FAS)	Epratuzumab 1200 mg every other week (FAS)	Epratuzumab 600 mg weekly (FAS)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	263	261	264	
Units: Percentage of responders				
number (not applicable)				
Responder	32.3	33.0	43.6	

Statistical analyses

No statistical analyses for this end point

Secondary: The percent of subjects meeting treatment response criteria at Week 12 according to a combined response index

End point title	The percent of subjects meeting treatment response criteria at Week 12 according to a combined response index
End point description:	
<p>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</p> <p>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</p>	
End point type	Secondary
End point timeframe:	
At Week 12	

End point values	Placebo (Weekly infusion) (FAS)	Epratuzumab 1200 mg every other week (FAS)	Epratuzumab 600 mg weekly (FAS)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	263	261	264	
Units: Percentage of responders				
number (not applicable)				
Responder	30.0	32.2	40.9	

Statistical analyses

No statistical analyses for this end point

Secondary: The percent of subjects meeting treatment response criteria at Week 36 according to a combined response index

End point title	The percent of subjects meeting treatment response criteria at Week 36 according to a combined response index
End point description:	
<p>Percentages are based on the number of subjects in the relevant treatment group within the Full Analysis Set (FAS). The combined response index incorporated criteria for achievement of responder status from the: British Isles Lupus Assessment Group Index (BILAG-2004)- improvement from study entry or no worsening in other organ systems, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI; Version 2000, also known as SLEDAI-2K) - no worsening compared to study entry, physician's global assessment of disease activity(PGA)- no worsening compared to study entry, and concomitant medications- no changes.</p> <p>The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.</p>	
End point type	Secondary
End point timeframe:	
At Week 36	

End point values	Placebo (Weekly infusion) (FAS)	Epratuzumab 1200 mg every other week (FAS)	Epratuzumab 600 mg weekly (FAS)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	263	261	264	
Units: Percentage of responders				
number (not applicable)				
Responder	32.7	33.0	36.7	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in daily corticosteroid dose at Week 24

End point title	Change from Baseline in daily corticosteroid dose at Week 24
End point description:	
Participants were grouped into 4 categories: Dose decreased by >50%, Dose decreased >0% to ≤50%, No change in dose and Dose increased or missing data. The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.	
End point type	Secondary
End point timeframe:	
At Week 24	

End point values	Placebo (Weekly infusion) (FAS)	Epratuzumab 1200 mg every other week (FAS)	Epratuzumab 600 mg weekly (FAS)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	263	261	264	
Units: Percentage of subjects				
number (not applicable)				
Dose decreased by >50%	4.6	10.0	8.7	
Dose decreased >0% to ≤50%	20.9	18.0	18.2	
No change in dose	48.3	46.7	52.7	
Dose increased or missing data	26.2	25.3	20.5	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in daily corticosteroid dose at Week 48

End point title	Change from Baseline in daily corticosteroid dose at Week 48
End point description:	
Participants were grouped into 4 categories: Dose decreased by >50%, Dose decreased >0% to ≤50%, No change in dose and Dose increased or missing data.	

The Full Analysis Set (FAS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of the study drug.

End point type	Secondary
End point timeframe:	
At Week 48	

End point values	Placebo (Weekly infusion) (FAS)	Epratuzumab 1200 mg every other week (FAS)	Epratuzumab 600 mg weekly (FAS)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	263	261	264	
Units: Percentage of participants				
number (not applicable)				
Dose decreased by >50%	6.5	13.8	14.8	
Dose decreased >0% to ≤50%	20.9	13.4	15.9	
No change in dose	35.7	35.6	36.7	
Dose increased or missing data	36.9	37.2	32.6	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

TEAEs were collected throughout the study (on or after first infusion of study drug and within 75 days of the last infusion), for an average of 4.5 years (starting in December 2010 and concluding in June 2015). The SS will be utilized for TEAE reporting.

Adverse event reporting additional description:

The Safety Set (SS) consisted of all subjects in the Randomized Set (RS) who had received at least 1 partial dose of study drug.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.0
--------------------	------

Reporting groups

Reporting group title	Placebo (Weekly infusion) (SS)
-----------------------	--------------------------------

Reporting group description:

Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles

Reporting group title	Epratuzumab 600 mg weekly (SS)
-----------------------	--------------------------------

Reporting group description:

600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles

Reporting group title	Epratuzumab 1200 mg every other week (SS)
-----------------------	---

Reporting group description:

1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles

Serious adverse events	Placebo (Weekly infusion) (SS)	Epratuzumab 600 mg weekly (SS)	Epratuzumab 1200 mg every other week (SS)
Total subjects affected by serious adverse events			
subjects affected / exposed	45 / 263 (17.11%)	50 / 264 (18.94%)	45 / 261 (17.24%)
number of deaths (all causes)	3	0	1
number of deaths resulting from adverse events	0	0	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon adenoma			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Papillary thyroid cancer			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian adenoma			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertensive crisis			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	2 / 261 (0.77%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	2 / 261 (0.77%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoedema			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Raynaud's phenomenon			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Temporal arteritis			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			

subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Abortion induced			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Pregnancy			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy on contraceptive			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	2 / 263 (0.76%)	3 / 264 (1.14%)	4 / 261 (1.53%)
occurrences causally related to treatment / all	0 / 2	1 / 4	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	1 / 263 (0.38%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			

subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 263 (0.00%)	4 / 264 (1.52%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiectasis			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Emphysema			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			

subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus pleurisy			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus pneumonitis			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleurisy			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary alveolar haemorrhage			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pulmonary hypertension			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary mass			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			

subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised anxiety disorder			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatinine decreased			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood pressure increased			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural			

complications			
Radius fracture			
subjects affected / exposed	1 / 263 (0.38%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post lumbar puncture syndrome			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Talipes			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Angina pectoris			

subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	2 / 261 (0.77%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus tachycardia			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus myocarditis			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Mitral valve incompetence			

subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Convulsion			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysarthria			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			

subjects affected / exposed	3 / 263 (1.14%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus encephalitis			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Memory impairment			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Migraine			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myoclonus			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nerve compression			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
VIIth nerve paralysis			

subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitis cerebral			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Noninfectious myelitis			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic neuritis			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraesthesia			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	2 / 261 (0.77%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	1 / 263 (0.38%)	2 / 264 (0.76%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			

subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Antiphospholipid syndrome			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Necrotising retinitis			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual impairment			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cataract			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal degeneration			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Pancreatitis acute			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal distension			

subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	2 / 263 (0.76%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mechanical ileus			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reflux gastritis			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 263 (0.38%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum intestinal			

subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal hypomotility			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Bile duct stenosis			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	3 / 263 (1.14%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic steatosis			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver injury			

subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Cutaneous lupus erythematosus			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Purpura			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	1 / 263 (0.38%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stevens-Johnson syndrome			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angioedema			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cutaneous vasculitis			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Lupus nephritis			
subjects affected / exposed	2 / 263 (0.76%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 2	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrotic syndrome			

subjects affected / exposed	2 / 263 (0.76%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proteinuria			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Goitre			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Systemic lupus erythematosus			
subjects affected / exposed	7 / 263 (2.66%)	6 / 264 (2.27%)	6 / 261 (2.30%)
occurrences causally related to treatment / all	0 / 7	1 / 6	0 / 6
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Compartment syndrome			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Flank pain			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periarthritis			

subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovitis			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint swelling			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck pain			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patellofemoral pain syndrome			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal pain			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	3 / 263 (1.14%)	4 / 264 (1.52%)	2 / 261 (0.77%)
occurrences causally related to treatment / all	2 / 3	1 / 4	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Urinary tract infection			

subjects affected / exposed	2 / 263 (0.76%)	3 / 264 (1.14%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	2 / 261 (0.77%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus chorioretinitis			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus viraemia			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis infected			

subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	3 / 263 (1.14%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	1 / 263 (0.38%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis aseptic			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculosis			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sialoadenitis			

subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin bacterial infection			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye infection toxoplasmal			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lobar pneumonia			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis bacterial			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas infection			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			

subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 263 (0.00%)	0 / 264 (0.00%)	1 / 261 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	0 / 263 (0.00%)	1 / 264 (0.38%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	1 / 263 (0.38%)	0 / 264 (0.00%)	0 / 261 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo (Weekly infusion) (SS)	Epratuzumab 600 mg weekly (SS)	Epratuzumab 1200 mg every other week (SS)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	151 / 263 (57.41%)	158 / 264 (59.85%)	145 / 261 (55.56%)
Vascular disorders			
Hypertension			
subjects affected / exposed	12 / 263 (4.56%)	17 / 264 (6.44%)	13 / 261 (4.98%)
occurrences (all)	12	17	15
Nervous system disorders			
Headache			
subjects affected / exposed	42 / 263 (15.97%)	33 / 264 (12.50%)	29 / 261 (11.11%)
occurrences (all)	68	50	39

Dizziness subjects affected / exposed occurrences (all)	13 / 263 (4.94%) 20	14 / 264 (5.30%) 16	10 / 261 (3.83%) 15
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all) Pyrexia subjects affected / exposed occurrences (all)	14 / 263 (5.32%) 17 17 / 263 (6.46%) 19	15 / 264 (5.68%) 18 13 / 264 (4.92%) 18	15 / 261 (5.75%) 31 8 / 261 (3.07%) 9
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all)	36 / 263 (13.69%) 51 19 / 263 (7.22%) 24 16 / 263 (6.08%) 18	25 / 264 (9.47%) 38 25 / 264 (9.47%) 41 16 / 264 (6.06%) 23	32 / 261 (12.26%) 41 15 / 261 (5.75%) 15 12 / 261 (4.60%) 14
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	12 / 263 (4.56%) 12	16 / 264 (6.06%) 19	12 / 261 (4.60%) 12
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	15 / 263 (5.70%) 16	9 / 264 (3.41%) 10	10 / 261 (3.83%) 11
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	19 / 263 (7.22%) 20	14 / 264 (5.30%) 14	14 / 261 (5.36%) 16
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	37 / 263 (14.07%) 46	37 / 264 (14.02%) 47	38 / 261 (14.56%) 49

Urinary tract infection			
subjects affected / exposed	44 / 263 (16.73%)	38 / 264 (14.39%)	37 / 261 (14.18%)
occurrences (all)	66	54	45
Nasopharyngitis			
subjects affected / exposed	21 / 263 (7.98%)	24 / 264 (9.09%)	15 / 261 (5.75%)
occurrences (all)	23	31	23
Sinusitis			
subjects affected / exposed	19 / 263 (7.22%)	20 / 264 (7.58%)	12 / 261 (4.60%)
occurrences (all)	23	23	17
Bronchitis			
subjects affected / exposed	23 / 263 (8.75%)	11 / 264 (4.17%)	13 / 261 (4.98%)
occurrences (all)	24	13	13

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 November 2011	<p>The protocol was amended for the following reasons:</p> <ul style="list-style-type: none">- To change the name and contact information of the Clinical Trial Biostatistician and Study Physician- To add additional exploratory endpoints for assessment of the SF-36 and flares- To clarify the guidance for use of oral corticosteroids for the investigator- To add the sampling time points for overall B and T cell levels during the study and to add a body weight measurement at Week 48. These were inadvertently omitted from the original protocol- To modify Inclusion Criterion #5 for female subjects to allow abstinence alone and condoms/diaphragm use without adjunct spermicide- To modify Exclusion Criterion #15 to clarify that subjects who had previously received Emab treatment were excluded from participation in this study- To update the withdrawal criteria list: subjects who received a live vaccine during the study must have been withdrawn- To increase the Wash-Out Period for the prohibited concomitant treatment TACI-Ig (Atacicept®) from 3 months to 10 months based on recently reported data. The screening window had been increased from 2 days to 5 days, to allow the Screening Period to be extended after discussion with and approval of the medical monitor if it was in the best interest of the subject, and to allow rescreening of subjects on a case-by-case basis at the discretion of the medical monitor- To add additional details to the description of the SF-36 assessment- To include a list of Anticipated SAEs in compliance with the recent US FDA guidance on safety reporting requirements for studies conducted under an open Investigational New Drug Application (Food and Drug Administration [FDA], Guidance for Industry and Investigators, 2010)- To modify the definition of the Pharmacokinetic Set (PKS) to include the requirement of at least 1 Emab plasma concentration measurement <p>In addition, a few clarifications, inconsistencies, and typographical errors had been made/corrected within the protocol text</p>
09 May 2014	<p>The protocol was amended at the request of the German Regulatory Authority PEI to clarify details of the BILAG assessment, to introduce a list of adverse events (AEs) of special interest, and to clarify further actions after identification of an AE of special interest. Additional changes were as follows:</p> <ul style="list-style-type: none">- Updated study contact information- Updated SAE reporting information- Revised the exploratory endpoints for assessment of flares and for assessment of the SLICC/ACR Damage score- Added an additional safety variable (incidence of hospitalizations/emergency room [ER] visits)- Clarified the guidance for use of oral corticosteroids for the investigator to note that subjects with increases in oral corticosteroids above the allowed levels for an SLE-related indication are considered nonresponders- Corrected the visit numbers cited in Exclusion Criterion #14- Updated Steroid conversion table with additional corticosteroids- Updated the text "Preparation and administration of Emab and placebo" in order to clarify that it is recommended, but not mandatory, that subjects be premedicated before receiving an iv infusion- Updated the text "Handling and storage requirements" in order to clarify the process to follow in case of out-of-range temperatures- Updated the version number of the European Quality of Life-5 Dimensions questionnaire to European Quality of Life-5 Dimensions 3 level version- Modified the generalized estimating equation (GEE) sensitivity analysis in order to avoid known violations of the missing completely at random assumption, and to be consistent with the current SAP. The original plan for assessing the impact of missing data on the primary endpoint has not changed- Modified the text "Safety analyses" to state that infection TEAEs will be identified by including all events in the coded SOC "Infections and infestations" rather than via a review of all AE terms prior to study unblinding, as originally planned

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported